Common Contracts
4 similar Commercialization Agreement contracts by Theravance Biopharma, Inc., Theravance Inc
EX-10.17 4 a2220057zex-10_17.htm EX-10.17 COMMERCIALIZATION AGREEMENT by and between THERAVANCE, INC. and CLINIGEN GROUP PLC Dated: March 8, 2013 COMMERCIALIZATION AGREEMENTCommercialization Agreement • May 5th, 2020 • New York
This Commercialization Agreement (“Agreement”) dated March 8, 2013, is made by and between THERAVANCE, INC., a Delaware corporation having its principal office at 901 Gateway Boulevard, South San Francisco, California 94080, United States (“Theravance”), and CLINIGEN GROUP PLC, Pitcairn House Crown Square, Centrum 100, BURTON UPON TRENT, DE14 2WW United Kingdom (“Clinigen”). Theravance and Clinigen may be referred to as a “Party” or together, the “Parties”.
COMMERCIALIZATION AGREEMENT by and between THERAVANCE, INC. and CLINIGEN GROUP PLC Dated: March 8, 2013Commercialization Agreement • May 7th, 2014 • Theravance Biopharma, Inc. • Pharmaceutical preparations • New York
This Commercialization Agreement (“Agreement”) dated March 8, 2013, is made by and between THERAVANCE, INC., a Delaware corporation having its principal office at 901 Gateway Boulevard, South San Francisco, California 94080, United States (“Theravance”), and CLINIGEN GROUP PLC, Pitcairn House Crown Square, Centrum 100, BURTON UPON TRENT, DE14 2WW United Kingdom (“Clinigen”). Theravance and Clinigen may be referred to as a “Party” or together, the “Parties”.
COMMERCIALIZATION AGREEMENT by and between THERAVANCE, INC. and CLINIGEN GROUP PLC Dated: March 8, 2013Commercialization Agreement • September 27th, 2013 • Theravance Biopharma, Inc. • Pharmaceutical preparations • New York
This Commercialization Agreement (“Agreement”) dated March 8, 2013, is made by and between THERAVANCE, INC., a Delaware corporation having its principal office at 901 Gateway Boulevard, South San Francisco, California 94080, United States (“Theravance”), and CLINIGEN GROUP PLC, Pitcairn House Crown Square, Centrum 100, BURTON UPON TRENT, DE14 2WW United Kingdom (“Clinigen”). Theravance and Clinigen may be referred to as a “Party” or together, the “Parties”.
COMMERCIALIZATION AGREEMENT by and between THERAVANCE, INC. and CLINIGEN GROUP PLC Dated: March 8, 2013Commercialization Agreement • May 1st, 2013 • Theravance Inc • Pharmaceutical preparations • New York
This Commercialization Agreement (“Agreement”) dated March 8, 2013, is made by and between THERAVANCE, INC., a Delaware corporation having its principal office at 901 Gateway Boulevard, South San Francisco, California 94080, United States (“Theravance”), and CLINIGEN GROUP PLC, Pitcairn House Crown Square, Centrum 100, BURTON UPON TRENT, DE14 2WW United Kingdom (“Clinigen”). Theravance and Clinigen may be referred to as a “Party” or together, the “Parties”.
